Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases.

Xiong Y, Torsoni AS, Wu F, Shen H, Liu Y, Zhong X, Canet MJ, Shah YM, Omary MB, Liu Y, Rui L.

Elife. 2018 Aug 2;7. pii: e34152. doi: 10.7554/eLife.34152.

2.

Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.

Li H, Canet MJ, Clarke JD, Billheimer D, Xanthakos SA, Lavine JE, Erickson RP, Cherrington NJ.

Drug Metab Dispos. 2017 Dec;45(12):1317-1325. doi: 10.1124/dmd.117.077644. Epub 2017 Oct 6.

3.

Hepatocyte TRAF3 promotes insulin resistance and type 2 diabetes in mice with obesity.

Chen Z, Canet MJ, Sheng L, Jiang L, Xiong Y, Yin L, Rui L.

Mol Metab. 2015 Oct 17;4(12):951-60. doi: 10.1016/j.molmet.2015.09.013. eCollection 2015 Dec.

4.

Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Canet MJ, Merrell MD, Hardwick RN, Bataille AM, Campion SN, Ferreira DW, Xanthakos SA, Manautou JE, A-Kader HH, Erickson RP, Cherrington NJ.

Drug Metab Dispos. 2015 Jun;43(6):829-35. doi: 10.1124/dmd.114.062703. Epub 2015 Mar 18.

5.

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ.

Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.

6.

Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.

Canet MJ, Merrell MD, Harder BG, Maher JM, Wu T, Lickteig AJ, Jackson JP, Zhang DD, Yamamoto M, Cherrington NJ.

Drug Metab Dispos. 2015 Jan;43(1):93-9. doi: 10.1124/dmd.114.060103. Epub 2014 Oct 27.

7.

Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ.

Toxicol Sci. 2014 Nov;142(1):45-55. doi: 10.1093/toxsci/kfu156. Epub 2014 Jul 31.

8.

Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Canet MJ, Cherrington NJ.

Expert Opin Drug Metab Toxicol. 2014 Sep;10(9):1209-19. doi: 10.1517/17425255.2014.936378. Epub 2014 Jul 3. Review.

9.

Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ.

J Pharmacol Exp Ther. 2014 Mar;348(3):452-8. doi: 10.1124/jpet.113.211284. Epub 2014 Jan 8.

10.

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ.

Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.

11.

The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis.

Cherrington NJ, Estrada TE, Frisk HA, Canet MJ, Hardwick RN, Dvorak B, Lux K, Halpern MD.

Am J Physiol Gastrointest Liver Physiol. 2013 Jan 1;304(1):G48-56. doi: 10.1152/ajpgi.00317.2012. Epub 2012 Nov 1.

12.

Altered arsenic disposition in experimental nonalcoholic fatty liver disease.

Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ.

Drug Metab Dispos. 2012 Sep;40(9):1817-24. doi: 10.1124/dmd.112.046177. Epub 2012 Jun 14.

13.

Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.

Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ.

Drug Metab Dispos. 2012 Mar;40(3):450-60. doi: 10.1124/dmd.111.041095. Epub 2011 Nov 23.

14.

Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ.

Drug Metab Dispos. 2011 Dec;39(12):2395-402. doi: 10.1124/dmd.111.041012. Epub 2011 Aug 30.

15.

Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ.

Drug Metab Dispos. 2010 Dec;38(12):2293-301. doi: 10.1124/dmd.110.035006. Epub 2010 Aug 30.

Supplemental Content

Loading ...
Support Center